This page uses content from Wikipedia and is licensed under CC BY-SA.

Nisoldipine

Nisoldipine
Skeletal formula of nisoldipine
Ball-and-stick model of the nisoldipine molecule
Clinical data
Trade namesSular, Baymycard, Syscor
AHFS/Drugs.comMonograph
MedlinePlusa696009
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability4–8%
Protein binding>99%
MetabolismCYP3A4
Elimination half-life7–12 hours
Excretion70–80% via urine
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.058.534 Edit this at Wikidata
Chemical and physical data
FormulaC20H24N2O6
Molar mass388.414 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Nisoldipine is a pharmaceutical drug used for the treatment of chronic angina pectoris and hypertension. It is a calcium channel blocker of the dihydropyridine class. It is sold in the United States under the proprietary name Sular. Nisoldipine has tropism for cardiac blood vessels.[1]

It was patented in 1975 and approved for medical use in 1990.[2]

Contraindications

Nisoldipine is contraindicated in people with cardiogenic shock, unstable angina, myocardial infarction, and during pregnancy and lactation.[3]

Adverse effects

Common side effects are headache, confusion, fast heartbeat, and edema. Hypersensitivity reactions are rare and include angioedema.[3]

Interactions

The substance is metabolized by the liver enzyme CYP3A4. Consequently, CYP3A4 inducers such as rifampicin or carbamazepine could reduce the effectiveness of nisoldipine, while CYP3A4 inhibitors such as ketoconazole increase the amount of nisoldipine in the body more than 20-fold. Grapefruit juice also increases nisoldipine concentrations by inhibiting CYP3A4.[3]

Pharmacology

Mechanism of action

Nisoldipine is a calcium channel blocker that selectively inhibits L-type calcium channels.[3]

References

  1. ^ Knorr, Andreas M. (1995). "Why is nisoldipine a specific agent in ischemic left ventricular dysfunction?". The American Journal of Cardiology. 75 (13): E36–E40. doi:10.1016/S0002-9149(99)80446-9.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495.
  3. ^ a b c d Haberfeld, H, ed. (2019). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Syscor 5 mg-Filmtabletten.

External links